secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alector, Inc. (ALEC)
CIK:        0001653087
Form:       8-K
Filed at:   2024-11-25T23:59:59+00:00
Accession:  0000950170-24-130564
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 2.05, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alector AL002 Phase 2 fails primary endpoint; cuts workforce 17%
----------------------------------------------------------------

- AL002 did not slow Alzheimer's progression on CDR-SB; no benefit on secondary endpoints or biomarkers.
- Stopping long-term extension of INVOKE-2 study; reducing workforce by ~41 employees (17% of staff).
- Restructuring charges estimated at $3.9 million, primarily severance and benefits, to be paid by H1 2025.
- Cash and investments of $457.2M as of Sep 30, 2024 expected to fund operations through 2026.
- Topline data for latozinemab Phase 3 in FTD-GRN expected late 2025/early 2026; AL101/GSK4527226 Phase 2 enrollment over one-third.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1653087/000095017024130564/0000950170-24-130564-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1653087/000095017024130564/alec-20241125.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-130564

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer